LDV20 Chromium: An Ingredient Explainer on the Fourth Active in an Australian Listed Medicine
LDV20 Chromium Explainer
- Product context: Explainer about Chromium as it appears in LDV20, an Australian Listed Medicine (AUST L 502251) sponsored by Pure Australia Pty Ltd under the OZNEX brand.
- Dose context: LDV20 is formulated with all four active ingredients — Policosanol (20 mg per recommended daily dose), Berberine, Milk Thistle (standardised to silymarin), Chromium — supplied as 120 capsules per box (4 × 30-capsule blister packs).
- Regulator: Therapeutic Goods Administration (TGA); product listed on the Australian Register of Therapeutic Goods (ARTG).
- Educational scope: This article explains what Chromium is, what its accepted nutrient role is, and what the published research reports at the ingredient level. Scientific references discussed relate to the individual ingredient Chromium and do not constitute clinical studies conducted on LDV20 itself.
LDV20 Chromium: An Ingredient Explainer on the Fourth Active in an Australian Listed Medicine
Editorial Notice
This article has been prepared by the editorial team at Pure Australia for educational purposes.
It combines publicly available regulatory information, published scientific literature and ingredient-level context. It does not include a customer-experience narrative; readers seeking that format should consult the prior editorial in this series.
Scientific references discussed relate to Chromium as an individual ingredient under various research conditions, and do not represent clinical studies conducted on LDV20 itself.
LDV20 is an Australian Listed Medicine. Always read the label and follow the directions for use.
Chromium is the last of the four active ingredients on the LDV20 product page, completing the cardiovascular / metabolic / hepatic / endocrine formulation rationale that is documented on the LDV20 Official Information Center. This article explains what Chromium is, what its accepted nutrient role is (per the U.S. National Institutes of Health), and what the published research reports about it as an individual ingredient.
1 · Chromium — the trace element
Chromium is a transition metal that occurs in several oxidation states in nature. The form documented in nutritional research is trivalent chromium — Cr(III). Cr(III) is recognised as an essential trace element for human physiology and is found naturally in many foods; a federal consumer-level fact sheet exists at the NIH ODS Chromium Consumer Fact Sheet, with the more detailed clinician-level entry at the NIH ODS Chromium Health Professional Fact Sheet.
Within LDV20, Chromium is one of four active ingredients. The manufacturer's description of the four-ingredient rationale — and Chromium's role within it as the macronutrient-metabolism limb — is documented on the LDV20 product page and the LDV20 Official Information Center.
2 · Chromium's accepted nutrient role
The most-cited summary of Chromium's nutrient role is the NIH ODS Health Professional Fact Sheet. It frames Chromium's biology in three practical points:
- Chromium is identified as an essential trace element required in small amounts.
- The element is documented as contributing to normal macronutrient metabolism.
- The Adequate Intake (AI) level for Chromium is set at 35 mcg/day for adults and children aged 4 and older.
These three points are the closest the literature comes to a regulator-grade baseline for Chromium. From there, the research community's evidence on higher-dose supplementation for specific outcomes — glycaemic control, anthropometrics, body composition — becomes more mixed; this is the subject of §5.
None of this baseline context is, in itself, a statement about LDV20. The AI value and the macronutrient-metabolism role both describe the ingredient.
3 · LDV20's label position for Chromium in a four-ingredient formula
LDV20 is formulated with all four active ingredients in the single pack — Policosanol (20 mg per recommended daily dose), Berberine, Milk Thistle (silymarin) and Chromium. The manufacturer describes the four ingredients as providing complementary support for cardiovascular, metabolic, hepatic and macronutrient metabolism functions — within normal range.
For Chromium specifically, that means the LDV20 product page maps the ingredient onto the macronutrient metabolism limb of the formulation rationale, consistent with the wording used by the NIH ODS and consistent with what an Australian Listed Medicine is permitted to claim.
4 · Chromium under the Australian Listed Medicine framework
Australian Listed Medicines operate under a tightly delimited claims framework. The framework rules that matter for a reader comparing the LDV20 label wording to Chromium research:
- TGA: AUST numbers on medicine labels — the labelling rules governing how an AUST L number appears on pack.
- TGA: Listed medicines overview — the framework under which LDV20 (AUST L 502251) is supplied.
- TGA ARTG: LDV20 (502251) — the public listing entry, which is how a consumer can verify the product.
Under this framework, an AUST L product may only support or maintain healthy physiological function within normal range. It may not be claimed to diagnose, treat, cure or prevent any disease. The Chromium wording on the LDV20 product page reflects this permitted scope.
5 · Published research on Chromium as an individual ingredient
Published studies have investigated Chromium as an individual ingredient under various research conditions. These studies evaluated the ingredient itself rather than LDV20 specifically. The body of evidence is most frequently summarised around three themes:
| Year | Source | Type | Reported focus (ingredient-level) |
|---|---|---|---|
| Updated 2024 | NIH ODS — Chromium Health Professional Fact Sheet | US federal fact sheet | Sets Chromium AI at 35 mcg/day for adults; reviews evidence on supplementation under various conditions. |
| Updated 2024 | NIH ODS — Chromium Consumer Fact Sheet | US federal consumer fact sheet | Consumer-level summary of Cr(III) and its dietary context. |
| 2025 | StatPearls — Chromium Deficiency | Clinician-level reference entry | Reviews Chromium as a trace element, deficiency states and related physiology. |
| 2014 | Suksomboon et al. — meta-analysis | Meta-analysis | Investigated Chromium supplementation alone or combined for glycaemic control. |
| 2016 | Costello et al. — narrative review | Narrative review of glycemic control | Reviewed Chromium-only evidence on glycaemic outcomes. |
| 2024 | Vajdi et al. — T2DM meta-analysis | Meta-analysis in T2DM | Reported no significant reduction in body weight, BMI, waist circumference or fat mass in T2DM Chromium cohorts. |
| 2023 | Wan et al. — JACC Advances | Cardiometabolic risk review | Reviewed prior intravenous and oral Chromium-only evidence. |
The studies in the table above cover Chromium as an individual ingredient. They do not evaluate LDV20 itself.
6 · Evidence balance — null-effect studies to consider alongside positive findings
Anevidence-balanced ingredient explainer has to include the studies that didn't find the proposed effect. Chromium supplementation is one of those areas where the literature is genuinely uneven and where, for any health writer, a balanced citation graph is part of the duty of care:
- Vajdi et al., 2024 (T2DM meta-analysis) found no significant reductions in body weight, BMI, waist circumference or fat mass in their pooled analysis of Chromium supplementation in patients with type 2 diabetes.
- The broader 2010-era summary by Wang et al., 2010 reached the more nuanced conclusion that documented-chromium-deficiency states respond to Chromium supplementation, but that the value of supplementation for non-deficient adults is contested.
- Long-term total parenteral nutrition literature (e.g. Freund et al., 1979) establishes that severe Chromium deficiency can arise in clinical deficiency states — but is not generalisable to typical adults obtaining dietary Chromium.
These caveats are deliberately included because the ingredient-level literature is mixed. None of the studies cited here evaluated LDV20 itself.
7 · Chromium's role in the LDV20 four-ingredient model
LDV20 is structured so that each of the four ingredients targets a different physiological pathway:
| Ingredient | Pathway focus (per LDV20 product page) | Anchor ingredient-level research |
|---|---|---|
| Policosanol (20 mg per recommended daily dose) | Cardiovascular / lipid balance | Sugarcane meta-analysis, 2017 |
| Berberine | Metabolic / glucose | PMC review, 2021 |
| Milk Thistle (silymarin) | Hepatic / antioxidant | StatPearls, 2024 |
| Chromium | Macronutrient metabolism | NIH ODS Fact Sheet |
The four-ingredient rationale is documented on the OZNEX Collection and the LDV20 Official Information Center. The ingredient-level research cited above for Policosanol, Berberine, Milk Thistle, and Chromium — across Article 003, Article 004, the Milk Thistle / silymarin piece, and this article — covers each pathway individually. None of these studies evaluated LDV20 itself.
8 · FAQ — Chromium and LDV20
What is Chromium?
Trivalent Chromium (Cr(III)) is a transition metal classified as an essential trace element. It is documented as contributing to normal macronutrient metabolism. See the NIH ODS Consumer Fact Sheet.
What is the recommended Adequate Intake (AI) for Chromium?
Per the NIH ODS Health Professional Fact Sheet, the Adequate Intake (AI) for Chromium is 35 mcg/day for adults and children aged 4 and older.
Is Chromium research the same as LDV20 research?
No. The Chromium studies cited in this article evaluated Chromium as an individual ingredient under various research conditions. None of these studies evaluated LDV20 itself.
Is the Chromium evidence base consistent?
The picture is mixed. The NIH ODS fact sheet summarises the federal-grade baseline; meta-analyses such as Suksomboon 2014 and Vajdi 2024 reach different conclusions for different endpoints. Both reference sets involve Chromium as the sole tested ingredient.
Where does Chromium appear on the LDV20 label?
Chromium is one of the four active ingredients on the LDV20 label, in the formulation rationale described on the LDV20 Official Information Center.
Is LDV20 an Australian Listed Medicine?
Yes. LDV20 is listed as AUST L 502251 on the ARTG, sponsored by Pure Australia Pty Ltd, and manufactured in a TGA-GMP facility.
Where do I read the manufacturer's own information?
- LDV20 product page (Korean store)
- LDV20 product page (English store)
- LDV20 Official Information Center
- LDV20 FAQ
- OZNEX full range
9 · References
Australian regulators
Chromium — published research on the individual ingredient
- NIH ODS — Chromium Health Professional Fact Sheet
- NIH ODS — Chromium Consumer Fact Sheet
- StatPearls — Chromium Deficiency
- Suksomboon et al., 2014 (meta-analysis)
- Costello et al., 2016 (narrative review)
- Vajdi et al., 2024 (T2DM null-effect meta-analysis)
- Wan et al., 2023 (JACC Advances)
- Wang et al., 2010 (Current concepts)
- Freund et al., 1979 (TPN deficiency)
- NIH Office of Dietary Supplements — search portal
Other LDV20 ingredients (ingredient-level research only)
Pure Australia internal pages referenced in this article
- Pure Australia — Home
- Pure Australia — Korean store
- OZNEX Collection
- LDV20 product page (Korean store)
- LDV20 product page (English store)
- LDV20 Official Information Center
- LDV20 FAQ
- Our Story
- Pure Australia blog index
- Article 001 — LDV20 Policosanol Explainer (20 mg)
- Article 002 — LDV20 Editorial Review
- Article 003 — LDV20 Policosanol Explainer (standalone)
- Article 004 — LDV20 Berberine Explainer
- Article 005 — LDV20 Milk Thistle / Silymarin Explainer
Editorial Disclaimer
This article is published by Pure Australia for educational and informational purposes.
It combines publicly available regulatory information with scientific literature on the individual ingredient Chromium.
Scientific references discussed relate to Chromium as an individual ingredient unless otherwise stated and do not represent clinical studies conducted on LDV20 itself.
LDV20 is an Australian Listed Medicine entered on the Australian Register of Therapeutic Goods (ARTG).
Always read the label and follow the directions for use.
If symptoms persist, worsen, or if you have concerns regarding your health, consult a qualified healthcare professional.